Literature DB >> 31164455

A Systematic Review and Network Meta-Analysis of Regorafenib and TAS-102 in Refractory Metastatic Colorectal Cancer.

Mohamad Bassam Sonbol1, Raed Benkhadra2, Zhen Wang3, Belal Firwana4, Daniel J Walden1, Kabir Mody5, Joleen M Hubbard6, M Hassan Murad3, Daniel H Ahn1, Tanios Bekaii-Saab7.   

Abstract

BACKGROUND: Regorafenib at different dosing strategies and TAS-102 are treatment options for refractory metastatic colorectal cancer (mCRC). We aimed to evaluate the comparative effectiveness evidence supporting these different strategies.
MATERIALS AND METHODS: We searched different databases for randomized controlled trials evaluating TAS-102 or regorafenib in patients with refractory mCRC who failed prior oxaliplatin, irinotecan, and fluoropyrimidine. Outcomes of interest included overall survival (OS) and progression-free survival (PFS). The overall effect was pooled using the DerSimonian random effects model. We conducted network meta-analysis based on White's multivariate meta-regression to pool evidence from direct and indirect comparisons.
RESULTS: Six trials at low risk of bias (2,445 patients) were included. Direct comparisons showed that Rego 160 and TAS-102 as monotherapy were superior to best-supportive care (BSC) in terms of PFS (Rego 160: hazard ratio [HR], 0.4; 95% confidence ratio [CI], 0.26-0.63; TAS-102: HR, 0.46 CI, 0.40-0.52) and OS (Rego 160: HR, 0.67; CI, 0.48-0.93; TAS-102: HR, 0.67; CI, 0.57-0.80). Network analysis showed no statistically difference in PFS or OS between Rego 160 and TAS-102. Rego 80+ was superior to BSC in terms of OS (HR, 0.44; CI, 0.23-0.84) and PFS (HR, 0.37; CI, 0.21-0.66). Rego 80+ was associated with statistically nonsignificant improvement in OS and PFS compared with TAS-102 and Rego 160.
CONCLUSION: Regorafenib 160 and TAS-102 appear to have similar efficacy. Rego 80+ is shown to be superior to BSC. A trend for improved OS was observed with Rego 80+ versus Rego 160 or TAS 102. IMPLICATIONS FOR PRACTICE: Regorafenib at a dose of 160 mg and TAS-102 appear to have similar efficacy in patients with refractory metastatic colorectal cancer. Regorafenib with a dose escalation strategy is superior to best-supportive care. Given its tolerability and the observed trend in survival benefit compared with regorafenib 160, dose escalation strategy of regorafenib (80+) may be the preferred option in this setting. © AlphaMed Press 2019.

Entities:  

Keywords:  Refractory metastatic colorectal cancer; Regorafenib; TAS‐102

Year:  2019        PMID： 31164455      PMCID： PMC6738316          DOI： 10.1634/theoncologist.2019-0189

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


  14 in total

Review 1.  Advanced colorectal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up.

Authors:  E Van Cutsem; J Oliveira
Journal:  Ann Oncol       Date:  2009-05       Impact factor: 32.976

2.  Randomized trial of TAS-102 for refractory metastatic colorectal cancer.

Authors:  Robert J Mayer; Eric Van Cutsem; Alfredo Falcone; Takayuki Yoshino; Rocio Garcia-Carbonero; Nobuyuki Mizunuma; Kentaro Yamazaki; Yasuhiro Shimada; Josep Tabernero; Yoshito Komatsu; Alberto Sobrero; Eveline Boucher; Marc Peeters; Ben Tran; Heinz-Josef Lenz; Alberto Zaniboni; Howard Hochster; James M Cleary; Hans Prenen; Fabio Benedetti; Hirokazu Mizuguchi; Lukas Makris; Masanobu Ito; Atsushi Ohtsu
Journal:  N Engl J Med       Date:  2015-05-14       Impact factor: 91.245

3.  Improved time to treatment failure with an intermittent oxaliplatin strategy: results of CONcePT.

Authors:  H S Hochster; A Grothey; L Hart; K Rowland; R Ansari; S Alberts; N Chowhan; R K Ramanathan; M Keaton; J D Hainsworth; B H Childs
Journal:  Ann Oncol       Date:  2014-03-07       Impact factor: 32.976

4.  Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS.

Authors:  T Yoshino; D Arnold; H Taniguchi; G Pentheroudakis; K Yamazaki; R-H Xu; T W Kim; F Ismail; I B Tan; K-H Yeh; A Grothey; S Zhang; J B Ahn; M Y Mastura; D Chong; L-T Chen; S Kopetz; T Eguchi-Nakajima; H Ebi; A Ohtsu; A Cervantes; K Muro; J Tabernero; H Minami; F Ciardiello; J-Y Douillard
Journal:  Ann Oncol       Date:  2018-01-01       Impact factor: 32.976

5.  Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial.

Authors:  Jin Li; Shukui Qin; Ruihua Xu; Thomas C C Yau; Brigette Ma; Hongming Pan; Jianming Xu; Yuxian Bai; Yihebali Chi; Liwei Wang; Kun-Huei Yeh; Feng Bi; Ying Cheng; Anh Tuan Le; Jen-Kou Lin; Tianshu Liu; Dong Ma; Christian Kappeler; Joachim Kalmus; Tae Won Kim
Journal:  Lancet Oncol       Date:  2015-05-13       Impact factor: 41.316

6.  Results of a Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Trifluridine/Tipiracil (TAS-102) Monotherapy in Asian Patients With Previously Treated Metastatic Colorectal Cancer: The TERRA Study.

Authors:  Jianming Xu; Tae Won Kim; Lin Shen; Virote Sriuranpong; Hongming Pan; Ruihua Xu; Weijian Guo; Sae-Won Han; Tianshu Liu; Young Suk Park; Chunmei Shi; Yuxian Bai; Feng Bi; Joong Bae Ahn; Shukui Qin; Qi Li; Changping Wu; Dong Ma; Donghu Lin; Jin Li
Journal:  J Clin Oncol       Date:  2017-12-07       Impact factor: 44.544

7.  Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.

Authors:  Axel Grothey; Eric Van Cutsem; Alberto Sobrero; Salvatore Siena; Alfredo Falcone; Marc Ychou; Yves Humblet; Olivier Bouché; Laurent Mineur; Carlo Barone; Antoine Adenis; Josep Tabernero; Takayuki Yoshino; Heinz-Josef Lenz; Richard M Goldberg; Daniel J Sargent; Frank Cihon; Lisa Cupit; Andrea Wagner; Dirk Laurent
Journal:  Lancet       Date:  2012-11-22       Impact factor: 79.321

8.  TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial.

Authors:  Takayuki Yoshino; Nobuyuki Mizunuma; Kentaro Yamazaki; Tomohiro Nishina; Yoshito Komatsu; Hideo Baba; Akihito Tsuji; Kensei Yamaguchi; Kei Muro; Naotoshi Sugimoto; Yasushi Tsuji; Toshikazu Moriwaki; Taito Esaki; Chikuma Hamada; Takanori Tanase; Atsushi Ohtsu
Journal:  Lancet Oncol       Date:  2012-08-28       Impact factor: 41.316

Review 9.  Therapeutic potential of TAS-102 in the treatment of gastrointestinal malignancies.

Authors:  Godefridus J Peters
Journal:  Ther Adv Med Oncol       Date:  2015-11       Impact factor: 8.168

10.  The Cochrane Collaboration's tool for assessing risk of bias in randomised trials.

Authors:  Julian P T Higgins; Douglas G Altman; Peter C Gøtzsche; Peter Jüni; David Moher; Andrew D Oxman; Jelena Savovic; Kenneth F Schulz; Laura Weeks; Jonathan A C Sterne
Journal:  BMJ       Date:  2011-10-18
View more
  3 in total

1.  Systematic review and network meta-analyses of third-line treatments for metastatic colorectal cancer.

Authors:  Thomas Walter; Neil S Hawkins; Richard F Pollock; Fabien Colaone; Suki Shergill; Paul J Ross
Journal:  J Cancer Res Clin Oncol       Date:  2020-07-27       Impact factor: 4.553

2.  Systematic Review and Meta-Analysis of Multitargeted Tyrosine Kinase Inhibitors in Patients With Intractable Metastatic Colorectal Cancer.

Authors:  Zhenzhen Gao; Chenxi Cao; Yi Bao; Yaohua Fan; Gang Chen; Peng Fu
Journal:  Technol Cancer Res Treat       Date:  2020 Jan-Dec

3.  Bioequivalence and Pharmacokinetic Evaluation of Two Oral Formulations of Regorafenib: An Open-Label, Randomised, Single-Dose, Two-Period, Two-Way Crossover Clinical Trial in Healthy Chinese Volunteers Under Fasting and Fed Conditions.

Authors:  Qian Zhang; Zhiqiang Wang; Jingying Wu; Zhen Zhou; Renpeng Zhou; Wei Hu
Journal:  Drug Des Devel Ther       Date:  2021-07-29       Impact factor: 4.162
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.